<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00864201</url>
  </required_header>
  <id_info>
    <org_study_id>PAH-CTD-2007</org_study_id>
    <nct_id>NCT00864201</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate the Use of Bosentan in Patients With Exercise Induced Pulmonary Arterial Hypertension Associated With Connective Tissue Disease</brief_title>
  <official_title>A Pilot Study to Evaluate the Effect of Bosentan in Patients With Exercise Induced Pulmonary Arterial Hypertension Associated With Connective Tissue Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hamilton Health Sciences Corporation</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Actelion</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>McMaster University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objectives of this exploratory study are to evaluate the effects of bosentan on&#xD;
      hemodynamics (via cardiac catheterization) during exercise in patients with Pulmonary&#xD;
      Arterial Hypertension (PAH) who have abnormal hemodynamics during exercise but normal&#xD;
      hemodynamics at rest. The authors hypothesize that early treatment may change the course of&#xD;
      disease progression by improving hemodynamics during exercise, thus delaying disease&#xD;
      progression.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Not yet recruiting</last_known_status>
  <start_date>April 2009</start_date>
  <completion_date type="Anticipated">April 2010</completion_date>
  <primary_completion_date type="Anticipated">April 2010</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The primary outcome is the change in the following hemodynamics during exercise: pulmonary vascular resistance (PVR), mean pulmonary arterial pressure (mPAP), cardiac output∕cardiac input (CO∕CI), mean right arterial pressure (mRAP)</measure>
    <time_frame>6 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in hemodynamics at rest: pulmonary vascular resistance (PVR), mean pulmonary arterial pressure (mPAP), cardiac output/cardiac input (CO∕CI), mean right arterial pressure (mRAP)</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">10</enrollment>
  <condition>Hypertension, Pulmonary</condition>
  <condition>Connective Tissue Disease</condition>
  <arm_group>
    <arm_group_label>bosentan</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>bosentan</intervention_name>
    <description>bosentan 62mg bid x 4 weeks, followed by bosentan 125mg bid x 20 weeks</description>
    <arm_group_label>bosentan</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Men or women ≥ 18 years of age&#xD;
&#xD;
          -  For female patients, only non-pregnant women who are surgically sterile,&#xD;
             postmenopausal or have documented infertility (over 50 years of age and amenorrheic&#xD;
             for at least 1 year), or those of childbearing potential using one of the following&#xD;
             methods of contraception:&#xD;
&#xD;
               -  Barrier-type devices (e.g., condom, diaphragm) used ONLY in combination with a&#xD;
                  spermicide. A double-barrier method is recommended.&#xD;
&#xD;
               -  Intrauterine devices (IUDs)&#xD;
&#xD;
               -  Oral contraceptives, if used in combination with a barrier method&#xD;
&#xD;
          -  Body weight of 40 kg or higher&#xD;
&#xD;
          -  Patients diagnosed with connective tissue disease&#xD;
&#xD;
          -  Hemodynamics at rest, based on cardiac catheterization, should be as follows:&#xD;
&#xD;
               -  Mean pulmonary arterial pressure (mPAP) : 18 - 25 mmHg&#xD;
&#xD;
               -  PCWP ≤ 15 mmHg&#xD;
&#xD;
          -  Hemodynamics during exercise, based on cardiac catheterization, should be as follows:&#xD;
             mPAP &gt; 30 mmHg&#xD;
&#xD;
          -  Provide written informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  PAH associated with any other condition&#xD;
&#xD;
          -  Severe obstructive lung disease : FEV1∕ FVC &lt;0.5&#xD;
&#xD;
          -  Total lung capacity &lt;60% of normal predicted value&#xD;
&#xD;
          -  Unable or unwilling have a cardiac catheterization procedure&#xD;
&#xD;
          -  Acute or chronic impairment (other than dyspnea), limiting the ability to comply with&#xD;
             study requirements (6-MWT)&#xD;
&#xD;
          -  Psychotic, addictive or other disorder limiting the ability to provide informed&#xD;
             consent or to comply with study requirements&#xD;
&#xD;
          -  Moderate to severe hepatic impairment, i.e., Child-Pugh Class B or C&#xD;
&#xD;
          -  AST and ∕or ALT &gt; 3 times uln&#xD;
&#xD;
          -  Hemoglobin concentration &gt; 25% below the lower limit of normal&#xD;
&#xD;
          -  Systolic blood pressure &lt; 85 mm Hg&#xD;
&#xD;
          -  Pregnancy or breast-feeding&#xD;
&#xD;
          -  Treatment or planned treatment with another investigational drug&#xD;
&#xD;
          -  Treatment with an endothelin receptor antagonist, phosphodiesterase type 5 inhibitor,&#xD;
             or with prostanoids (excluding acute administration during a catheterization procedure&#xD;
             to test vascular reactivity) within 2 months of inclusion&#xD;
&#xD;
          -  Treatment with calcineurin-inhibitors (i.e., cyclosporine A and tacrolimus),&#xD;
             fluconazole, glibenclamide (glyburide) within 1 week of study start;&#xD;
&#xD;
          -  Known hypersensitivity to bosentan or any of the excipients&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Christine Bradley</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hamilton Health Sciences Corporation</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Christine Bradley, MD</last_name>
    <phone>905-546-9993</phone>
    <email>mkenney@bellnet.ca</email>
  </overall_contact>
  <location>
    <facility>
      <name>Victoria Medical Center</name>
      <address>
        <city>Hamilton</city>
        <state>Ontario</state>
        <zip>L8L 5G4</zip>
        <country>Canada</country>
      </address>
    </facility>
    <investigator>
      <last_name>Christine Bradley, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>March 2009</verification_date>
  <study_first_submitted>March 17, 2009</study_first_submitted>
  <study_first_submitted_qc>March 17, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 18, 2009</study_first_posted>
  <last_update_submitted>March 17, 2009</last_update_submitted>
  <last_update_submitted_qc>March 17, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 18, 2009</last_update_posted>
  <responsible_party>
    <name_title>Dr. Christine Bradley</name_title>
    <organization>Victoria Medical Centre</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pulmonary Arterial Hypertension</mesh_term>
    <mesh_term>Hypertension, Pulmonary</mesh_term>
    <mesh_term>Hypertension</mesh_term>
    <mesh_term>Connective Tissue Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bosentan</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

